Lo Andrew
SEC Form 4 insider trading activity
Lo Andrew has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Jun 24, 2026.
On the most recent filing, Lo Andrew is listed as Director at BridgeBio Pharma, Inc. Inside the rolling window, Lo Andrew reported no open-market purchases and 2 open-market sales totaling $6.3M in BBIO. The largest disclosed transaction in the window is a sale of 55,000 BBIO shares on Nov 18, 2025, worth $3.6M.
Companies traded
Other insiders at BBIO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$6.3M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Lo Andrew made?
Lo Andrew has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company since 2025.
Which companies does Lo Andrew trade?
Lo Andrew has filed SEC Form 4 disclosures for 1 company, including BBIO.
When was Lo Andrew's most recent SEC Form 4 filing?
Lo Andrew's most recent SEC Form 4 filing on Tracefour is dated Jun 24, 2026.
What is Lo Andrew's total buy and sell value in the current window?
Inside the rolling retention window, Lo Andrew bought $0 and sold $6.3M based on SEC Form 4 filings.
What was Lo Andrew's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 55,000 BBIO shares on 2025-11-18, worth $3.6M, per SEC Form 4 filings.